Remepy
Develops Hybrid Drugs combining prescription medicines with AI-driven therapeutic apps
$36MSeries A
Role not disclosedKC
Key1 Capital
Activity from announced rounds
Activity in this selectionAI · Series A
Key1 Capital is an Israeli growth-technology manager whose investment records identify Lyte, Remepy and Xsight.
Recorded funding activity
Lyte develops robotic perception systems. Remepy combines prescription medicines with therapeutic software, while Xsight designs connectivity chips for computing infrastructure. The companies pursue distinct hardware and healthcare products.
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $36M 1 disclosed · full round size, not this investor’s share